Supplementary Data, Supplementary Figures and Legends 1-13 from Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9

Supplementary figure 1. Validation of synthetic lethal interaction between OGT inhibition and AT7519 in LNCaP cells. Supplementary figure 2. Validation of synthetic lethal interaction between OSMI-2 and AT7519 in additional cell lines. Supplementary figure 3. Combination of OSMI-2 with AT7519 induces cells death in prostate cancer cells but not in cells derived from normal prostate epithelia. Supplementary figure 4. Characterization of RNA-seq data of cells treated with OGT inhibitor OSMI-2. Supplementary figure 5. OGT inhibition decreases phosphorylation of the carboxyterminal domain of RNA polymerase II. Supplementary figure 6. AT7519 enhances the effects of OGT inhibition by blocking the upregulation of OGT in PC3 cells. Supplementary figure 7. Summary of the RNA-seq data. Supplementary figure 8. Specific CDK9 inhibitor NVP2 is synthetically lethal in combination with OGT inhibition to LNCaP prostate cancer cells. Supplementary figure 9. OGT inhibition potentiates the anti-proliferative effects of CDK9 inhibitors Dinaciclib and SB1317 on prostate cancer cells. Supplementary figure 10. Knockdown of CDK9 sensitizes LNCaP prostate cancer cells to OGT inhibition. Supplementary figure 11. Combination of OSMI-2 with AT7519 further decreases the mRNA abundance of most mRNAs with half-life less than 4 hours. Supplementary figure 12. Determination of CDK9 inhibitor dose suitable for organoid experiments. Supplementary figure 13. Validation of synthetic lethality between inhibitors of OGT and CDK9 using models of castration-resistant prostate cancer (CRPC).